By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Oncology. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, "In the TNM seventh edition, a prognostic grouping for prostate cancer incorporating prostate-specific antigen and Gleason score was advocated. The present study was carried out to evaluate and validate prognostic grouping in prostate cancer patients."
The news reporters obtained a quote from the research from the University of Tokyo, "The 15259 study patients treated with primary androgen deprivation therapy were enrolled in the Japan Study Group of Prostate Cancer. Overall survival was stratified by tumor-nodes-metastasis, Gleason score and prostate-specific antigen, and extensively analyzed. The accuracy of grouping systems was evaluated by the concordance index. The 5-year overall survival in prognostic grouping-I, IIA, IIB, III and IV was 90.0%, 88.3%, 84.8%, 80.6% and 57.1%, respectively. When considering subgroup stratification, the 5-year overall survival of subgroups prognostic grouping-IIA, IIB, III and IV was 80.9 approximate to 90.5%, 75.4 approximate to 91.8%, 75.7 approximate to 89.0% and 46.9 approximate to 86.2%, respectively. When prognostic grouping-IIB was subclassified into IIB1 (except IIB2) and IIB2 (T1-2b, prostate-specific antigen >20, Gleason score 8, and T2c, Gleason score 8), the 5-year overall survival of IIB2 was significantly lower than that of IIB1 (79.4% and 87.3%, P100 or Gleason score 8), the 5-year overall survival of prognostic grouping-IV1 was superior to that of IV2 (72.9% and 49.5%, P<0.0001). Prognostic groupings were reclassified into modified prognostic groupings, divided into modified prognostic grouping-A (prognostic grouping-I, IIA, and IIB1), modified prognostic grouping-B (prognostic grouping-IIB2 and III), modified prognostic grouping-C (prognostic grouping-IV1) and modified prognostic grouping-D (prognostic grouping-IV2). The concordance index of prognostic grouping and modified prognostic grouping for overall survival was 0.670 and 0.685, respectively. Prognostic grouping could stratify the prognosis of prostate cancer patients. However, there is considerable variation among the prognostic grouping subgroups."
According to the news reporters, the research concluded: "Thus, the use of a modified prognostic grouping for patients treated with primary androgen deprivation therapy is advisable."
For more information on this research see: Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy. International Journal of Urology, 2013;20(9):880-888. International Journal of Urology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; International Journal of Urology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1442-2042)
Our news correspondents report that additional information may be obtained by contacting T. Kimura, University of Tokyo, Adv Sci & Technol Res Center, Dept. of Strateg Invest Comprehens Canc Network, Tokyo, Japan. Additional authors for this research include M. Onozawa, J. Miyazaki, K. Kawai, H. Nishiyama, S. Hinotsu and H. Akaza (see also Oncology).
Keywords for this news article include: Asia, Tokyo, Japan, Therapy, Hormones, Oncology, Immunology, Kallikreins, Endopeptidases, Prostate Cancer, Serine Proteases, Neoplasm Antigens, Peptide Hydrolases, Prostatic Neoplasms, Biological Tumor Markers, Prostate-Specific Antigen, Prostatic Secretory Proteins, Androgens and Anabolic Steroids
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .